Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Pyxis Oncology (PYXS)
NASDAQ:PYXS
Holding PYXS?
Track your performance easily
PYXS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.35 - $6.85
Previous Close$4.19
Volume793.62K
Average Volume (3M)528.71K
Market Cap
$249.16M
Enterprise Value$124.88M
Total Cash (Recent Filing)$144.82M
Total Debt (Recent Filing)$20.54M
Price to Earnings (P/E)―
Beta2.33
Next Earnings
Mar 20, 2025EPS Estimate
-$0.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.05
Shares Outstanding59,465,729
10 Day Avg. Volume780,886
30 Day Avg. Volume528,712
Standard Deviation0.31
R-Squared0.04
Alpha-0.00696
Financial Highlights & Ratios
Price to Book (P/B)1.62
Price to Sales (P/S)15.23
Price to Cash Flow (P/CF)-4.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue7.47
Enterprise Value/Gross Profit69.38
Enterprise Value/Ebitda-2.17
Forecast
1Y Price Target
$9.25Price Target Upside120.76% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Pyxis Oncology News
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentThe update on the Phase 1 study of PYX-201 is considered a significant catalyst for Pyxis Oncology due to its potential to be both first-in-class and best-in-class if successful.
Financial PerformancePyxis Oncology is trading at a relatively low valuation for a novel ADC, which suggests that any positive signals from the PYX-201 study could lead to a favorable market response.
Innovation And TechnologyPYX-201 was developed using Pfizer’s FACT platform, which enables site-specific conjugation, highlighting its advanced and precise design features.
Bears Say
Efficacy ConcernsThe therapeutic window will be an active point of discussion amongst investors, especially for certain tumor types where the efficacy bar for emerging standards of care has increased.
Investor CautionMany investors have been cautious and are on the sidelines due to the novel ADC approach targeting a non-internalizing target, rather than the typical internalizing targets.
Stock SentimentThe short interest in Pyxis Oncology's stock is relatively high at 15.1% of the float.
---
Ownership Overview
8.71% Insiders
5.88% Mutual Funds
23.90% Other Institutional Investors
53.56% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PYXS FAQ
What was Pyxis Oncology’s price range in the past 12 months?
Pyxis Oncology lowest stock price was $1.35 and its highest was $6.85 in the past 12 months.
What is Pyxis Oncology’s market cap?
Currently, no data Available
When is Pyxis Oncology’s upcoming earnings report date?
Pyxis Oncology’s upcoming earnings report date is Mar 20, 2025 which is in 118 days.
How were Pyxis Oncology’s earnings last quarter?
Pyxis Oncology released its earnings results on Nov 12, 2024. The company reported -$0.35 earnings per share for the quarter, missing the consensus estimate of -$0.318 by -$0.032.
Is Pyxis Oncology overvalued?
According to Wall Street analysts Pyxis Oncology’s price is currently Undervalued.
Does Pyxis Oncology pay dividends?
Pyxis Oncology does not currently pay dividends.
What is Pyxis Oncology’s EPS estimate?
Pyxis Oncology’s EPS estimate is -$0.31.
How many shares outstanding does Pyxis Oncology have?
Pyxis Oncology has 59,465,730 shares outstanding.
What happened to Pyxis Oncology’s price movement after its last earnings report?
Pyxis Oncology reported an EPS of -$0.35 in its last earnings report, missing expectations of -$0.318. Following the earnings report the stock price went down -2.532%.
Which hedge fund is a major shareholder of Pyxis Oncology?
Among the largest hedge funds holding Pyxis Oncology’s share is Perceptive Advisors LLC. It holds Pyxis Oncology’s shares valued at N/A.
---
Pyxis Oncology Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$9.25 (120.76% Upside)
$9.25 (120.76% Upside)
Blogger Sentiment
Bullish
PYXS Sentiment 66%
Sector Average 73%
Sector Average 73%
Hedge Fund Trend
Decreased
By 2.3M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.6%
Last 30 Days ▼ 4.6%
Last 30 Days ▼ 4.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
175.65%
12-Months-Change
Fundamentals
Return on Equity
-39.34%
Trailing 12-Months
Asset Growth
4.62%
Trailing 12-Months
Company Description
Pyxis Oncology
Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.
---
PYXS Stock 12 Month Forecast
Average Price Target
$9.25
▲(120.76% Upside)
Technical Analysis
Best Analysts Covering PYXS
1 Year
1 Year Success Rate
7/8 ratings generated profit
1 Year Average Return
+44.11%
reiterated a buy rating 11 days ago
Copying Sam Slutsky's trades and holding each position for 1 Year would result in 87.50% of your transactions generating a profit, with an average return of +44.11% per trade.
---